A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

Eitemau Tebyg

• Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma
  gan: Zhu, Yun-Rong, et al.
  Cyhoeddwyd: (2015)
• Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
  gan: Cerniglia, George J., et al.
  Cyhoeddwyd: (2012)
• The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared to Rapamycin in Renal Cell Carcinoma
  gan: Cho, Daniel C., et al.
  Cyhoeddwyd: (2010)
• Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
  gan: YANG, XIAOYU, et al.
  Cyhoeddwyd: (2016)
• Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines
  gan: Ishikawa, Chie, et al.
  Cyhoeddwyd: (2018)